Article Text

PDF
Selected highlights from other veterinary journals

Statistics from Altmetric.com

Effect of pimobendan in dogs with preclinical mitral valve disease

A. Boswood, J. Haggstrom, S. G. Gordon, G. Wess, R. L. Stepien,

M. A. Oyama and others

MYXOMATOUS mitral valve disease (MMVD) is the most common cardiovascular disease in dogs and can lead to congestive heart failure (CHF). Dogs with MMVD are categorised into four stages: those at risk of developing the disease (stage A); those with evidence of mitral regurgitation and no signs of CHF (stage B); those with signs of CHF (stage C); and those with signs of CHF refractory to treatment (stage D).

A number of therapies are considered effective in dogs with stage C disease, including pimobendan, which has been shown to improve survival. Despite the effectiveness of such treatments, median survival time for dogs with stage C disease is less than one year. Therefore, any treatment effective in prolonging the preclinical period could have a major impact on longevity of affected dogs; however, currently there is no consensus about the effectiveness of medical treatment at stage B. The aim of this study was to evaluate the effectiveness of pimobendan in dogs with stage B disease.

Three-hundred and sixty dogs with preclinical MMVD that were …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.